This technical application poster, originally showcased at ISCT 2024, shares data demonstrating the development and application of a fully automated high throughput screen (HTS) of extensive lipid libraries to identify and optimize effective lipid nanoparticles (LNPs). It shows a comprehensive automated high-throughput method to systematically screen large libraries of LNPs, identifying formulations with optimal transfection efficiency in immune cells.

LNPs are an emerging technology with potential for delivering and improving the bioavailability of therapeutic agents such as drugs or genetic materials by efficiently encapsulating and transporting payloads within the body. HTSs play a pivotal role in optimizing effective drug delivery. For LNPs this allows for the methodical selection of lipid formulations to achieve desired stability and release kinetics combined with high uptake by the target cells.

Download this poster to learn how LNPs can optimize your effective drug delivery.

About OmniaBio
As a dedicated cell and gene therapy CDMO, OmniaBio's vision is to manufacture a disease-free future. Headquartered in Ontario, Canada, our core values of collaborative partnership converge with deep industry experience and innovation using the latest technologies to drive the future of cell and gene therapy manufacturing.